Search - tctmd.com

Displaying 261 - 280 of 342

Sort: Relevancy | Date

News Daily News

Higher BMI Linked to Increased Risk of CHD, Hypertension, and Diabetes

Michael O'Riordan

July 06, 2017

News Daily News

Optimal Cardiovascular Health Not Offset by Poor Health as a Whole

Ashley Lyles

June 20, 2017

News Daily News

Growing Gap in CVD Risk Factor Control Between Rich and Poor

Michael O'Riordan

June 08, 2017

News Daily News

Therapies Aimed at New Genetic Target Show Early Promise for Lowering Triglycerides

Todd Neale

May 26, 2017

News Features

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Michael O'Riordan

May 23, 2017

News Conference News EuroPCR 2017

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

Michael O'Riordan

May 18, 2017

News Daily News

Registry Study Supports Curbing Cholesterol Screening for Young Adults Because of Low Overall Risk

Yael L. Maxwell

May 15, 2017

News Daily News

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

Michael O'Riordan

May 12, 2017

News Conference News EAS 2017

Diet, Exercise, and Gut Bacteria Play Different, Overlapping Roles in Cardiometabolic Disease Development

Yael L. Maxwell

May 03, 2017

News Conference News EAS 2017

Is Atherosclerosis an LDL-Cholesterol or Immune Disease? The Answer May Be Both

Yael L. Maxwell

April 25, 2017

News

Mortality and CVD Decline in Patients With Diabetes, but Biggest Strides Seen for Nonfatal Outcomes

Michael O'Riordan

April 13, 2017

News Daily News

Midlife Vascular Risk Factors Linked to Amyloid Plaques in Alzheimer’s

Alison Palkhivala

April 11, 2017

News Conference News ACC 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Yael L. Maxwell

March 23, 2017

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

News Conference News ACC 2017

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

CARAT: Novel HDL Mimetic Fails to Show Benefit in Coronary Atherosclerosis After ACS

Yael L. Maxwell

March 18, 2017

News Conference News ACC 2017

ORION-1: Novel LDL-Lowering Treatment Could Reduce Costs, Increase Adherence Over PCSK9s

Yael L. Maxwell

March 17, 2017

News Conference News ACC 2017

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

Yael L. Maxwell

March 17, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

Timing and Dose Matters When It Comes to Statin Therapy Before CABG Surgery

Michael O'Riordan

March 16, 2017

Advertisement

Higher BMI Linked to Increased Risk of CHD, Hypertension, and Diabetes

Optimal Cardiovascular Health Not Offset by Poor Health as a Whole

Growing Gap in CVD Risk Factor Control Between Rich and Poor

Therapies Aimed at New Genetic Target Show Early Promise for Lowering Triglycerides

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

Registry Study Supports Curbing Cholesterol Screening for Young Adults Because of Low Overall Risk

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

Diet, Exercise, and Gut Bacteria Play Different, Overlapping Roles in Cardiometabolic Disease Development

Is Atherosclerosis an LDL-Cholesterol or Immune Disease? The Answer May Be Both

Mortality and CVD Decline in Patients With Diabetes, but Biggest Strides Seen for Nonfatal Outcomes

Midlife Vascular Risk Factors Linked to Amyloid Plaques in Alzheimer’s

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

CARAT: Novel HDL Mimetic Fails to Show Benefit in Coronary Atherosclerosis After ACS

ORION-1: Novel LDL-Lowering Treatment Could Reduce Costs, Increase Adherence Over PCSK9s

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Timing and Dose Matters When It Comes to Statin Therapy Before CABG Surgery

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content